- Home
- JAGX vs INM Comparison
JAGX vs INM Comparison
Compare JAGX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- INM
- Stock Information
- Founded
- JAGX 2013
- INM 1981
- Country
- JAGX United States
- INM Canada
- Employees
- JAGX N/A
- INM N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- INM Health Care
- Exchange
- JAGX Nasdaq
- INM Nasdaq
- Market Cap
- JAGX 3.5M
- INM 3.2M
- IPO Year
- JAGX N/A
- INM N/A
- Fundamental
- Price
- JAGX $2.58
- INM $3.33
- Analyst Decision
- JAGX Strong Buy
- INM
- Analyst Count
- JAGX 1
- INM 0
- Target Price
- JAGX $60.00
- INM N/A
- AVG Volume (30 Days)
- JAGX 90.6K
- INM 9.5M
- Earning Date
- JAGX 08-12-2025
- INM 05-12-2025
- Dividend Yield
- JAGX N/A
- INM N/A
- EPS Growth
- JAGX N/A
- INM N/A
- EPS
- JAGX N/A
- INM N/A
- Revenue
- JAGX $11,552,000.00
- INM $4,920,990.00
- Revenue This Year
- JAGX $22.41
- INM N/A
- Revenue Next Year
- JAGX $30.00
- INM N/A
- P/E Ratio
- JAGX N/A
- INM N/A
- Revenue Growth
- JAGX 13.93
- INM N/A
- 52 Week Low
- JAGX $2.43
- INM $1.72
- 52 Week High
- JAGX $110.75
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- JAGX 28.76
- INM 59.24
- Support Level
- JAGX $2.61
- INM $2.26
- Resistance Level
- JAGX $3.30
- INM $5.50
- Average True Range (ATR)
- JAGX 0.28
- INM 0.40
- MACD
- JAGX 0.06
- INM 0.11
- Stochastic Oscillator
- JAGX 6.56
- INM 37.04
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.